Medscape www.medscape.com

References for:
Efficacy and Tolerability of Irbesartan, an Angiotensin II Receptor Antagonist, in Primary Hypertension A Double-Blind, Placebo-Controlled, Dose-Titration Study

[Clin Drug Invest 15(3):217-227, 1998. © 1998 Adis International Limited]

  1. Cazaubon C, Gougat J, Bousquet F, et al. Pharmacological characterization of SR 47436, a new nonpeptide AT1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther 1993; 265: 826-34
  2. Bauer JH, Reams GP. The angiotensin II type 1 receptor antagonists: a new class of antihypertensive drugs. Arch Intern Med 1995; 155: 1361-8
  3. Ellis ML, Patterson JH. A new class of antihypertensive therapy: angiotensin II receptor antagonists. Pharmacotherapy 1996; 16: 849-60
  4. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988- 1991. Hypertension 1995; 25: 305-13
  5. Stockwell DH, Madhavan S, Cohen H, et al. The determinants of hypertension awareness, treatment, and control in an insured population. Am J Public Health 1994; 84: 1768-74
  6. Joint National Committee on Prevention D, Evaluation. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Bethesda: National Institutes of Health, 1997
  7. Ribstein J, Sissmann J, Picard A, et al. Effects of the angiotensin II antagonist SR 47436 (BMS 186295) on the pressor response to exogenous angiotensin II and the renin-angiotensin system in sodium replete normal subjects [abstract]. J Hypertens 1994; 12: 131
  8. Ribstein J, Picard A, Armagnac C, et al. Full antagonism of pressor response to exogenous angiotensin II (AII) by single-dose irbesartan in normotensive subjects [abstract]. J Hypertens 1997; 15 Suppl. 4: S117
  9. van den Meiracker AH, Admiraal PJJ, Janssen JA, et al. Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension. Hypertension 1995; 25: 22-9
  10. Pool JL, Guthrie RM, Littlejohn T, et al. The antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension [abstract]. Am J Hypertens 1996; 9: 152A
  11. Lasseter KC, Marino MR, Langenbacher KM, et al. Pharmacodynamics of irbesartan in subjects with mild-to-moderate hypertension. Am J Hypertens 1997; 10: 121
  12. van den Meiracker A, Janssen J, Admiraal P, et al. Dose-finding study with angiotensin II receptor antagonist SR 47436 (BMS 186295) in essential hypertension [abstract]. J Hypertens 1994; 12: S94
  13. Janiak P, Pillon A, Prost J-F, et al. Role of angiotensin subtype 2 receptor in neointima formation after vascular injury. Hypertension 1992; 20: 737-45
  14. Johnston CI. Angiotensin receptor antagonists: focus on losartan. Lancet 1995; 346: 1403-7
  15. Lacourcière Y, Brunner H, Irwin R, et al. Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens 1994; 12: 1387-93
  16. Weber MA, Byyny RL, Pratt JH, et al. Blood pressure effects of the angiotensin II receptor blocker, losartan. Arch Intern Med 1995; 155: 403-11
  17. Gradman AH, Arcuri KE, Goldberg AI, et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995; 25: 1345-50
  18. Nelson E, Arcuri K, Ikeda L, et al. Efficacy and safety of losartan in patients with essential hypertension [abstract]. Am J Hypertens 1992; 5: 19A-20A
  19. Franks H, Hermann WM, Magin SG. Comparison of the efficacy and safety of candesartan cilexetil 4, 8 and 12mg with placebo and enalapril 10mg in patients with mild to moderate hypertension [abstract]. Am J Hypertens 1997; 10: 90A
  20. Elmfeldt D, George M, Hubner R, et al. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect. J Hum Hypertens 1997; 11 Suppl. 2: S49-53
  21. Hagmann M, Burnier M, Nussberger J, et al. Natriuretic and hormonal effects of SR 47436 (BMS 186295), a new angiotensin II receptor antagonist in normotensive volunteers [abstract]. Am J Hypertens 1994; 7: 13A
  22. McIntyre M, MacFadyen RJ, Meredith PA, et al. Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR47436/BMS-186295) on blood pressure and neurohormonal effects in salt-deplete men. J Cardiovasc Pharmacol 1996; 28: 101-6